Pseudomonas Tailocin Lysates for Resistant E. Coli Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Escherichia coli infections, particularly urinary tract infections and gastrointestinal infections, are challenging due to increasing antibiotic resistance, with existing treatments facing difficulties in effectively combating multidrug-resistant strains and foodborne illnesses, and current methods fail to address the lack of effective prevention and/or treatment of contamination by resistant strains.
Innovation Solution
A composition comprising a cell lysate from Pseudomonas fluorescens, Pseudomonas chlororaphis, and Pseudomonas syringae species, which produces tailocins, is used in the prevention or the treatment of contamination by Escherichia coli, comprising a composition comprising a composition comprising a composition comprising a composition comprising a cell lysate, wherein the composition comprises a composition comprising a cell produces at least one tailocin from a Pseudomonas bacterium selected from the group consisting of Pseudomonas bacterium selected from the group consisting of Pseudomonas fluorescens, Pseudomonas chlororaphis, Pseudomonas koreensis and Pseudomonas syringae species, for use in the prevention or the treatment in a subject of a contamination or an infection by an Escherichia coli strain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat E. coli infections, then bacterial infections can be eliminated, but antibiotic resistance develops making treatments ineffective
Solution Approach 1:
The patent uses bacteriophages as intermediary agents to deliver tailocins directly to target E. coli cells. The phage acts as a mediator that specifically transports the antibacterial compound to the intended target, avoiding non-specific effects and reducing the development of resistance compared to traditional antibiotics
Solution Approach 2:
The patent extracts and utilizes the tailocin component from bacteriophage particles as a standalone antibacterial agent. By separating the active antibacterial component (tailocin) from the complete phage structure, the invention creates a targeted therapy that eliminates bacteria through a specific mechanism different from traditional antibiotics, thereby avoiding antibiotic resistance
2Adaptability or versatility
If broad-spectrum antibiotics are used to combat multidrug-resistant strains, then more infections can be treated, but resistance to multiple antibiotic classes increases
Solution Approach 1:
The patent changes the fundamental parameter of the antibacterial mechanism from chemical inhibition (antibiotics) to physical disruption (tailocin-mediated cell lysis). This parameter change allows the treatment to be effective against multidrug-resistant strains without selecting for additional resistance mechanisms, as the action is mechanical rather than biochemical
Solution Approach 2:
The patent converts the harmful presence of multidrug-resistant bacteria into an opportunity to apply an alternative mechanism of action. By using tailocins that physically puncture cell membranes, the treatment turns the resistance problem into a benefit, as the physical disruption mechanism bypasses all chemical resistance mechanisms
3Reliability
If traditional antimicrobial methods are used, then common infections can be treated, but prevention and treatment of contamination by resistant strains is insufficient
Solution Approach 1:
The patent enables preliminary action by using tailocin-treated foods and surfaces to prevent contamination before it occurs. The composition can be applied in advance to create a protective barrier that prevents resistant E. coli from establishing infection, rather than waiting for treatment to be needed
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively prevents and treats Escherichia coli infections, including urogenital and gastrointestinal infections, by utilizing tailocins produced by Pseudomonas species, demonstrating broad-spectrum bactericidal activity against resistant strains, and can be applied in food products and intimate care products.
Implementation Method 1
They consist of a contractile (R-type) or non-contractile (F-type) sheath forming a rigid tube attached to a baseplate with a spike-shaped protein complex at its tip and associated receptor binding protein (RBP). These nanomachines kill upon contact with their targeted bacteria by puncturing their membranes leading to cell lysis
Data Source
Figure 1
Figure 2A~2D
Figure 3A~3B
AI summary
The present invention relates to antibacterial compounds efficient against Escherichia coli, i.e. a composition comprising a cell lysate, wherein the cell produces at least one tailocin from a Pseudomonas bacterium selected from the group consisting of Pseudomonas fluorescens, Pseudomonas chlororaphis, Pseudomonas koreensis and Pseudomonas syringae species, for use in the prevention or the treatment in a subject of a contamination or an infection by an Escherichia coli strain. It further relates to non-therapeutic uses of the same cell lysate for the prevention and/or the treatment of a contamination by an Escherichia coli strain in a food product or on a surface, and intimate care product or a food supplement comprising the cell lysate, as well as new nucleic acids encoding one or two original tailocins, expression vectors or cells comprising them, a cell lysate and its therapeutic and non-therapeutic uses.